Skip Ribbon Commands
Skip to main content

Lancet Oncology publication reports safety and efficacy of Holmium-166 SIRT after PRRT in neuroendocrine tumor patients

Terumo Europe N.V. and Quirem Medical B.V. are proud to share the latest key publication regarding holmium-166 (QuiremSpheres®) Selective Internal Radiation Therapy (SIRT). On February 26, 2020, the UMC Utrecht published their latest results in the Lancet Oncology Journal from the non-randomized HEPAR PLuS study. The study enrolled neuroendocrine tumor (NET) patients with liver disease for Holmium-166 SIRT after successful completion of 4 cycles of Peptide Receptor Radionuclide Therapy (PRRT).  

2/03/2020 - LEUVEN, BELGIUM

From data published on PRRT, it is known that NET patients with larger liver metastases have less favorable survival outcomes after PRRT1,2. In this study, it was investigated whether additional treatment of liver metastases using Holmium-166 SIRT improves the response rates for this group of patients. 

HEPAR PLuS proved that the additional radiation boost provided by Holmium-166 SIRT following PRRT resulted in a high liver objective response rate of 43 % and 47% after 3 and 6 months.

"By boosting treatment of liver disease with Holmium-166 SIRT in NET patients after PRRT, we expect to improve both overall survival and quality of life with a relatively well-tolerated therapy. This publication shows that we indeed see an additional tumor response in the liver," first author Dr. Arthur Braat comments.

"This is an important next step to show the importance of Holmium-166 SIRT in treating mNET patients by combining it with other treatment modalities such as PRRT." said Rijk de Jong, Medical Director of Quirem Medical. "We also believe that the individualized treatment planning approach of Holmium SIRT will further translate into enhanced efficacy and safety for the benefit of patients undergoing SIRT procedures."

"This is a very exciting milestone for QuiremSpheres® and the next step in building the future for SIRT." added Peter Coenen, President of Terumo Interventional Systems EMEA. "This publication further validates the importance of Holmium-166 SIRT and the individualized treatment planning you can perform when using Holmium SIRT. We at Terumo believe is a vital step to advance patient selection and optimize dosimetry to achieve better outcomes for mNET patients and liver cancer patients in general".

Holmium-166 SIRT is the only SIRT technology that uses the same microspheres for the work-up (QuiremScout®) and treatment (QuiremSpheres®), which aims to optimize patient selection and advance treatment planning.


About Terumo Europe

Terumo Europe is a core player in the EMEA healthcare market by providing best in class quality medical products and services. We are a strong actor of the Terumo Group by contributing to innovation and sustainable growth. Terumo Europe produces, distributes, markets and sells a vast range of medical devices in five main business units: Interventional Systems, Pharmaceutical Solutions, Medical Products, Cardiovascular Products and Diabetes Management. Terumo Europe EMEA headquarters and production.

facilities are located in Leuven (Belgium), production facility in Knowsley (UK), European Distribution Center in Genk (Belgium) and sales offices across EMEA.

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide, to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been bolstering healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.


About Quirem Medical

At Quirem Medical, we develop and commercialize the next-generation Selective Internal Radiation Therapy (SIRT) microspheres based on the radioisotope Holmium-166. We believe the treatment outcome of unresectable liver cancer with SIRT can be optimized with Holmium-166 microspheres, which can be visualized and quantified to improve SIRT patient selection, treatment planning and treatment verification. Our innovative Holmium-166 platform technology provides physicians a complete CE-marked SIRT solution including QuiremScout®, QuiremSpheres® and the supporting dosimetry software Q-SuiteTM.

1 J Strosberg et. al ;. J CLIN ONCOL 2016

2  J Strosberg, et al. Ann Oncol. 2018;29(Suppl8): Abstract 1316P